CN115120522A - 木犀草素及衍生物作为有效成分促进生发的组合物及应用 - Google Patents
木犀草素及衍生物作为有效成分促进生发的组合物及应用 Download PDFInfo
- Publication number
- CN115120522A CN115120522A CN202210926224.XA CN202210926224A CN115120522A CN 115120522 A CN115120522 A CN 115120522A CN 202210926224 A CN202210926224 A CN 202210926224A CN 115120522 A CN115120522 A CN 115120522A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- hair
- derivatives
- hair growth
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 72
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 235000009498 luteolin Nutrition 0.000 title claims abstract description 72
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 230000003779 hair growth Effects 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000001737 promoting effect Effects 0.000 title claims abstract description 31
- -1 luteolin galactoside Chemical class 0.000 claims abstract description 34
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 claims abstract description 10
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- RQJGBVDTAFXEIJ-UHFFFAOYSA-N 3-C-methylluteolin Chemical compound O1C2=CC(O)=CC(O)=C2C(=O)C(C)=C1C1=CC=C(O)C(O)=C1 RQJGBVDTAFXEIJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000002660 luteolin derivatives Chemical class 0.000 claims abstract description 3
- 210000004209 hair Anatomy 0.000 claims description 50
- 239000007788 liquid Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 239000003405 delayed action preparation Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000008266 hair spray Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 241000195940 Bryophyta Species 0.000 claims description 5
- 239000000118 hair dye Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 229940040145 liniment Drugs 0.000 claims description 5
- 235000011929 mousse Nutrition 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000000341 volatile oil Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 230000004044 response Effects 0.000 abstract description 5
- 201000004384 Alopecia Diseases 0.000 description 26
- 239000000463 material Substances 0.000 description 19
- 210000003780 hair follicle Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 230000003676 hair loss Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000024963 hair loss Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 231100000360 alopecia Toxicity 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 206010068168 androgenetic alopecia Diseases 0.000 description 4
- 201000002996 androgenic alopecia Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003662 hair growth rate Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 239000004334 sorbic acid Substances 0.000 description 4
- 229940075582 sorbic acid Drugs 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000003656 anti-hair-loss Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000008395 clarifying agent Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000024349 endocrine alopecia Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020604 functional milk Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002659 luteolin Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种促进生发的组合物,具体为一种木犀草素及衍生物作为有效成分促进生发的组合物及应用;组合物包括木犀草素及其衍生物与制剂辅料,木犀草素,又名3',4',5,7‑四羟黄酮,分子式为C15H10O6;木犀草素的衍生物为木犀草素葡萄糖苷、木犀草素半乳糖苷、木犀草素鼠李糖苷、木犀草素木糖苷、甲基木犀草素、羧甲基木犀草素、丙基木犀草素和羟丙基木犀草素;拓展了木犀草素及其衍生物的用途,同时为促进生发提供了新的组合物,具有见效快,治疗周期短的特点。
Description
技术领域
本发明涉及一种促进生发的组合物,具体为一种木犀草素及衍生物作为有效成分促进生发的组合物及应用。
背景技术
人体头发由毛干和毛囊两部分组成,其中毛干又可分为毛小皮、皮质、髓质三层结构,主要成分为角蛋白。毛小皮的上表皮和外表皮内含有丰富的高硫蛋白,能抵御外界物理化学因素的影响。皮质细胞由许多角蛋白构成的粗纤维、细纤维和原纤维组成,这些纤维均被包含在由高硫蛋白组成的细胞基质中并形成非常紧密的纤维束。在毛小皮细胞之间以及毛小皮与皮质细胞之间的细胞间隙中,还含有内部脂质——细胞膜络合物,起到毛小皮细胞之间以及毛小皮与皮质细胞之间的粘合作用。毛囊是头发生长和固定的器官,使头发生长遵循生长期、退行期、休止期三个阶段的周期性变化。毛囊的周期性变化受多种因素的调控,包括生长因子、细胞因子、激素、神经肽、药物和环境污染等,当大量的生长期毛发受到刺激而停止生长时,就会进入退行期和休止期,从而引起脱发。
各种形式的脱发是折磨人们的持续问题。男性和女性都可能患有脱发,这可能是由一种或多种因素共同导致的,包括遗传因素,激素因素,手术,创伤,化疗,衰老,某些药物副作用和压力。脱发发生的普遍性导致历史上不断努力寻找刺激头发生长和预防脱发的成分。脱发的种类有:雄激素性脱发、神经性脱发、内分泌脱发、营养性脱发、物理性脱发、化学性脱发、感染性脱发、症状性脱发、先天性脱发和季节性脱发。
雄激素性脱发主要为雄激素代谢异常导致的雄激素性脱发(又称脂溢性脱发),雄激素性脱发在脱发群里中占比达90%以上。雄激素经5α-还原酶生成二氢睾酮,二氢睾酮通过与细胞内的雄激素受体结合引起一系列反应,使毛囊出现进展性的微小化,生长期的毛发逐渐变细,进而毛发生长周期逐渐缩短,结果导致原本粗黑的毛发逐渐变成浅色的毳毛,最终由于毛囊萎缩消失,毳毛也脱落,形成前额部、冠状区和头顶部的秃发。
为了缓解脱发,人们发明了各种各样的防脱发洗护用品,但是,现有的防脱发洗护用品虽然具有一定的发脱发功效,但通常仅能针对某种脱发因素进行改善,然而,如上所述,造成脱发的原因有多种,而人体构造是十分复杂的,想要准确判定出具体的脱发因素是较为困难的,而且随着时间的推移,脱发因素也会发生变化,因此仅针对某种脱发因素进行改善,往往会导致防脱发的效果难以达到预期。
综上所述,研发一种可促进生发的有效成分组合物是一个有待解决的技术问题。
发明内容
本发明要解决的技术问题是克服现有的缺陷,提供一种木犀草素及衍生物作为有效成分促进生发的组合物及应用,拓展了木犀草素及其衍生物的用途,同时为促进生发提供了新的组合物,具有见效快,治疗周期短的特点。
为了解决上述技术问题,本发明提供了如下的技术方案:一种木犀草素及其衍生物作为有效成分促进生发的组合物,组合物包括木犀草素及其衍生物与制剂辅料。
木犀草素,又名3',4',5,7-四羟黄酮,分子式为C15H10O6;
木犀草素的衍生物为木犀草素葡萄糖苷、木犀草素半乳糖苷、木犀草素鼠李糖苷、木犀草素木糖苷、甲基木犀草素、羧甲基木犀草素、丙基木犀草素和羟丙基木犀草素。
为了解决上述技术问题,本发明提供了如下的技术方案:一种木犀草素及衍生物作为有效成分促进生发的组合物的应用,组合物可应用于洗发水、护发素、护发精华、护发精油、护发喷雾、生发水、发露、发膜、发胶、定发剂、摩丝、焗油膏及染发剂中的任意一种。
作为优选,组合物可应用于促进生发的药物。
作为优选,所述的药物可以为乳液、霜剂、丸剂、滴丸剂、颗粒剂、胶囊剂、涂剂、散剂、喷雾剂、巴布剂、口服液、汤剂、注射剂、控释制剂或缓释制剂中的任意一种。
本发明有益效果:
1、本发明针对目前临床上促进生发亟待解决的药物需求,发现了木犀草素及其衍生物可有效促进生发的新用途。
2、木犀草素及其衍生物相对于现有的西药,价格低廉,降低治疗成本,减轻患者经济负担,符合目前消费的需求。
3、木犀草素及其衍生物作为组合物或药物的有效成分,安全性良好、无毒副作用。
4、本发明的包含木犀草素及其衍生物作为有效成分的促进生发的组合物连续使用一个月即可见效,见效快,治疗周期短。、
附图说明
图1为本发明实施例各组小鼠毛囊数量的统计结果;
图2为本发明实施例各组小鼠毛发生长速度评分;
图3为本发明实施例各组小鼠体重的统计结果。
具体实施方式
以下对本发明的优选实施例进行说明,应当理解,此处所描述的优选实施例仅用于说明和解释本发明,并不用于限定本发明。
本发明首次公开了一种包含木犀草素及其衍生物作为有效成分的促进生发的组合物。所述组合物包括木犀草素及其衍生物与制剂辅料。本发明通过实验发现,木犀草素及其衍生物可以促进小鼠脱毛区毛发生长,提高其生长速度并增加毛囊数量,且具有无毒副作用,成本低和见效快的特点。
所述组合物包括木犀草素及其衍生物与制剂辅料。
木犀草素(Luteolin),又名3',4',5,7-四羟黄酮,分子式为C15H10O6,分子量为286.23,结构如图I所示:
木犀草素的衍生物为木犀草素葡萄糖苷、木犀草素半乳糖苷、木犀草素鼠李糖苷、木犀草素木糖苷、甲基木犀草素、羧甲基木犀草素、丙基木犀草素、羟丙基木犀草素。
进一步的,所述组合物包括,但不限于洗发水、护发素、护发精华、护发精油、护发喷雾、生发水、发露、发膜、发胶、定发剂、摩丝、焗油膏及染发剂中的任意一种。
本发明还提供一种包含木犀草素及其衍生物作为有效成分促进生发的药物,包含所述的促进生发的组合物。
进一步的,所述药物包括,但不限于乳液、霜剂、丸剂、滴丸剂、颗粒剂、胶囊剂、涂剂、散剂、喷雾剂、巴布剂、口服液、汤剂、注射剂、控释制剂或缓释制剂中的任意一种。
本发明还提供木犀草素及其衍生物在制备促进生发组合物中的应用;所述组合物选自包括,但不限于洗发水、护发素、护发精华、护发精油、护发喷雾、生发水、发露、发膜、发胶、定发剂、摩丝、染发剂及焗油膏组成的组中的任一形态。
本发明还提供木犀草素及其衍生物在制备促进生发药物中的应用。
进一步的,所述药物包括,但不限于乳液、霜剂、丸剂、滴丸剂、颗粒剂、胶囊剂、涂剂、散剂、喷雾剂、巴布剂、口服液、汤剂、注射剂、缓释制剂或控释制剂中的任意一种。
本发明还提供木犀草素及其衍生物作为唯一活性成分在制备所述组合物和药物中的应用。
本发明在具体实施时,可以按照如下方式进行,
实施例1
(1)小鼠分组及给药方法
除正常对照组外,其余组别小鼠背部全部脱毛。
动物分组:空白组、模型组、基质甘油葡糖苷组、木犀草素组、木犀草素葡萄糖苷组、木犀草素半乳糖苷组、木犀草素鼠李糖苷组、木犀草素木糖苷组、甲基木犀草素组、羧甲基木犀草素组、丙基木犀草素组、羟丙基木犀草素组、阳性米诺地尔搽剂组。各组的木犀草素及其衍生物和米诺地尔搽剂使用甘油葡糖苷溶解,甘油葡糖苷组给予基质甘油葡糖苷,每天给药2次,连续给药一个月后,取材,取各组小鼠去毛区皮肤,显微镜下统计毛囊数目。
(2)观测指标
①背部毛发生长情况
比较各组别小鼠背部脱毛区皮肤生长的程度,以评价生发的速度,无毛生长0分,浅毛长满脱毛区1分,新生毛长度与密度约为未脱毛区的一半2分,新生长与未脱毛区无差别3分(评分标准按照参考文献[杨亚军,王冬春,周秋贵,丁家宜.水溶性米诺地尔对C57BL/6小鼠毛发生长影响的研究[J].海峡药学,2007(07):34-36.]);
②皮肤内毛囊数
小鼠处死后,将背部皮肤组织固定后,石蜡切片HE染色统计皮肤内的毛囊数,以评价促进生发的功效。连续给药一个月后,拍摄各组小鼠背部去毛区的皮肤图片,模型组毛发生长较少,溶解基质甘油葡糖苷对毛发生长无显著影响,说明基质不存在促生发功效,木犀草素及其衍生物以及阳性药米诺地尔酊均可不同程度促进小鼠背部去毛区的毛发生长。对各组小鼠的皮肤取材,进行包埋切片,而后进行HE染色,毛囊统计结果如图1所示,木犀草素及其衍生物的毛囊数量相较于模型组明显增多;与空白组相比,模型组小鼠背部去毛区皮肤中的毛囊数量显著减少;基质甘油葡糖苷对毛发生长无明显影响;木犀草素及其衍生物组可显著增加小鼠背部去毛区皮肤的毛囊数量。各组小鼠毛发生长速度评分见图2,由图2可知,基质组与模型组的毛发生长速度评分基本相近,说明溶解基质无促进生发的功效;与模型组相比,木犀草素葡萄糖苷显著加速了小鼠背部去毛区的毛发生长速度。此外,图3的结果表明,给药一个月时间对小鼠的体重无明显影响,说明木犀草素及其衍生物对小鼠无毒副作用。
综上所述,可确定通过使用木犀草素及其衍生物可以达到以下技术效果:
(1)促进小鼠脱毛区毛发生长;
(2)提高毛发生长速度;
(3)增加毛囊数量;
(4)无毒副作用;
(5)连续给药一个月即可见效,见效快,治疗周期短;
本发明可根据成分种类、成分含量、剂型等产生多个实施方式。例如:
实施方式1:以木犀草素及其衍生物为有效成分的洗护产品;
可制备成选自包括,但不限于洗发水、护发素、护发精华、护发精油、护发喷雾、生发水、发露、发膜、发胶、定发剂、摩丝、染发剂及焗油膏组成的组中的任一形态。
实施方式2:以木犀草素及其衍生物为有效成分的乳液或霜剂;
通常将常温下呈半固态的称为霜剂,称流体状态的称为奶液或乳液,乳液是互不相溶的两种液体,其中一相以微小液滴分散于另一相中所形成的体系,通常把以液珠形式存在的一相称为分散相或内相另外一相称为分散介质或外相。
乳液或霜剂常用的辅料有:乳化剂、抗氧剂、增粘剂、pH调节剂、油质原料。
乳化剂:为形成稳定的乳状液,乳化剂的加入是必需的。
pH调节剂:为避免过强的刺激性和提高稳定性,常用缓冲溶液来稳定药液的pH值。常用的缓冲溶液有硼酸缓冲液、磷酸盐缓冲液等。
油质原料:乳液或霜剂中经常添加各类油质原料,对其成形、稳定或赋予色、香以及其它特性起作用,这些物质配方中用量不大,但却极其重要。主要包括油脂,如蜡类、烃类和合成油脂。
实施方式3:以木犀草素及其衍生物为有效成分的口服液;
以口服液为例,口服液是在汤剂、注射剂基础上发展起来的新剂型,具有剂量小、吸收较快、质量稳定、携带和服用方便、易于保存的优点,其含有多种有效成分,对质量和口感有很大的影响。在不改变主要活性成分结构和功能前提下,如何能最大限度的保留有效成分、改善口感是其选用辅料的一个难点。在口服液中添加辅料可以提高口感,改善澄清度,增强稳定性,提高产品质量。
口服液常用辅料有:溶剂、芳香剂、矫味剂、澄清剂、防腐剂等,这些辅料可同时加入,也可择其一加入,其中溶剂是必加的,可以采用水。不同的辅料组合有甜味剂、芳香剂、澄清剂或防腐剂,或甜味剂和防腐剂的组合,优选甜味剂和防腐剂的组合。部分辅料兼具增甜和增香的作用,此时只需加入一种辅料即可。
针对口服液,优选地,所述甜味剂包括,但不限于甜菊糖苷、木糖醇、阿斯巴甜和赤藓糖醇中的一种或多种。
针对口服液,优选地,所述防腐剂包括,但不限于对羟基苯甲酸酯、丁基羟基茴香醚、丁基羟基甲苯和山梨酸中的一种或多种。
防腐剂可选用包括,但不限于对羟基苯甲酸酯、丁基羟基甲苯或山梨酸,也可以组合使用。例如羟基苯甲酸酯与丁基羟基甲苯的组合,或丁基羟基甲苯与山梨酸的组合,或对羟基苯甲酸酯与山梨酸的组合,或对羟基苯甲酸酯、丁基羟基甲苯和山梨酸的组合。
针对口服液,优选地,所述芳香剂为水果香精。
针对口服液,优选地,所述澄清剂包括,但不限于壳聚糖和明胶中的一种或两种混合。
实施方式4:以木犀草素及其衍生物为有效成分的片剂;
片剂具有剂量准确,质量稳定,服用、携带及运输方便等优点。
针对片剂,所述制剂辅料包括稀释剂、粘合剂、润滑剂和崩解剂中一种或多种,优选稀释剂、粘合剂、润滑剂和崩解剂的组合。
针对片剂,优选地,所述稀释剂包括,但不限于纤维素类和无机盐类中的一种或多种。例如微晶纤维素、硫酸钙、磷酸氢钙及药用碳酸钙、甘露醇等,以增加原料体积助其成型的。
针对片剂,优选地,所述粘合剂包括,但不限于水、乙醇、羧甲基纤维素钠、羟丙基纤维素、甲基纤维素、乙基纤维素、明胶和聚乙烯吡咯烷酮等中的一种或多种。
针对片剂,优选地,所述润滑剂包括,但不限于硬脂酸镁、微粉硅胶、滑石粉、氢化植物油、聚乙二醇和月桂醇硫酸镁中的一种或多种。
针对片剂,优选地,所述崩解剂包括,但不限于低取代羟丙基、交联聚乙烯吡咯烷酮和交联羧甲基纤维素钠等中的一种或多种。
实施方式5:以木犀草素及其衍生物为有效成分的胶囊;
在本发明中,胶囊主要提高稳定性和生物利用度。所述制剂辅料为胶囊壳,所述胶囊壳为硬胶囊壳或软胶囊壳。
实施方式6:以木犀草素及其衍生物为有效成分的颗粒剂;
颗粒剂可以直接吞服,也可以用温水冲入水中饮入,应用和携带比较方便,溶出和吸收速度较快。颗粒剂所用的制剂辅料与片剂相似,涉及填充剂、粘合剂、润湿剂、崩解剂、润滑剂和薄膜包衣材料中的一种或多种。
针对颗粒剂,优选地,所述填充剂包括,但不限于纤维素类和无机盐类中的一种或多种。例如微晶纤维素、硫酸钙、磷酸氢钙及药用碳酸钙、甘露醇等,以增加原料体积助其成型的。
针对颗粒剂,优选地,所述粘合剂包括,但不限于水、乙醇、羧甲基纤维素钠、羟丙基纤维素、甲基纤维素、乙基纤维素、明胶和聚乙烯吡咯烷酮等中的一种或多种。
针对颗粒剂,优选地,所述润湿剂包括,但不限于水或乙醇或两者的混合。例如为硬脂酸镁、微粉硅胶、滑石粉、氢化植物油、聚乙二醇和月桂醇硫酸镁中的一种或多种。
针对颗粒剂,优选地,所述崩解剂包括,但不限于低取代羟丙基、交联聚乙烯吡咯烷酮和交联羧甲基纤维素钠等中的一种或多种。
针对颗粒剂,优选地,所述薄膜包衣材料包括,但不限于羟丙基甲基纤维素、聚乙二醇、醋酸纤维素酞酸酯和聚乙烯缩乙醛二乙胺醋酸酯中的一种或多种。
实施方式7:以木犀草素及其衍生物为有效成分的散剂。
本发明也可制成散剂,散剂便于分剂量和服用。
以饮料为例,将本发明的组合物制成不同风味的饮料,作为日常饮品将深受欢迎。
饮料所用的制剂辅料为澄清剂、防腐剂和香味剂中的至少一种。
本发明的组合物也可制成其它散剂,例如制成功能性奶粉,加入的辅料主要为奶粉,例如脱脂奶粉,脱脂无糖奶粉。
以上多个实施方式可调整单位产品中的剂量大小,以适应不同的用途,如药品、保健品、食品等。
综合以上实施例,本发明公开了一种包含木犀草素及其衍生物作为有效成分的促进生发的组合物。所述组合物包括木犀草素及其衍生物与制剂辅料。本发明通过实验发现,木犀草素及其衍生物可以促进小鼠脱毛区毛发生长,提高其生长速度并增加毛囊数量,且无毒副作用,成本低,见效快。因此,可以用木犀草素及其衍生物和制剂辅料制备促进生发的组合物或药物。
以上为本发明较佳的实施方式,本发明所属领域的技术人员还能够对上述实施方式进行变更和修改,因此,本发明并不局限于上述的具体实施方式,凡是本领域技术人员在本发明的基础上所作的任何显而易见的改进、替换或变型均属于本发明的保护范围。
Claims (4)
1.一种木犀草素及其衍生物作为有效成分促进生发的组合物,其特征在于,组合物包括木犀草素及其衍生物与制剂辅料,
木犀草素,又名3',4',5,7-四羟黄酮,分子式为C15H10O6;
木犀草素的衍生物为木犀草素葡萄糖苷、木犀草素半乳糖苷、木犀草素鼠李糖苷、木犀草素木糖苷、甲基木犀草素、羧甲基木犀草素、丙基木犀草素和羟丙基木犀草素。
2.一种木犀草素及衍生物作为有效成分促进生发的组合物的应用,其特征在于,组合物可应用于洗发水、护发素、护发精华、护发精油、护发喷雾、生发水、发露、发膜、发胶、定发剂、摩丝、焗油膏及染发剂中的任意一种。
3.如权利要求2所述的木犀草素及衍生物作为有效成分促进生发的组合物的应用,其特征在于,组合物可应用于促进生发的药物。
4.如权利要求3所述的木犀草素及衍生物作为有效成分促进生发的组合物的应用,其特征在于,所述的药物可以为乳液、霜剂、丸剂、滴丸剂、颗粒剂、胶囊剂、涂剂、散剂、喷雾剂、巴布剂、口服液、汤剂、注射剂、控释制剂或缓释制剂中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210926224.XA CN115120522A (zh) | 2022-08-03 | 2022-08-03 | 木犀草素及衍生物作为有效成分促进生发的组合物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210926224.XA CN115120522A (zh) | 2022-08-03 | 2022-08-03 | 木犀草素及衍生物作为有效成分促进生发的组合物及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115120522A true CN115120522A (zh) | 2022-09-30 |
Family
ID=83385900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210926224.XA Pending CN115120522A (zh) | 2022-08-03 | 2022-08-03 | 木犀草素及衍生物作为有效成分促进生发的组合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115120522A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116999484A (zh) * | 2023-10-07 | 2023-11-07 | 云南英格生物技术有限公司 | 紫苏籽油粕提取物在制备5α-还原酶抑制剂中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070036742A1 (en) * | 2005-08-09 | 2007-02-15 | Access Business Group International Llc | Methods and compositions for modulating hair growth or regrowth |
JP2010150177A (ja) * | 2008-12-25 | 2010-07-08 | Maruzen Pharmaceut Co Ltd | Fgf−7産生促進剤、igf−1産生促進剤及びhgf産生促進剤 |
US20140341829A1 (en) * | 2011-12-22 | 2014-11-20 | Akzo Nobel Chemicals International B.V. | Bioactive compositons having hair anti aging activity |
JP2017066145A (ja) * | 2016-10-07 | 2017-04-06 | 国立大学法人九州大学 | 毛母細胞増殖促進剤、毛乳頭細胞増殖促進剤、脱毛症の外用薬及び脱毛症の外用薬の生産方法 |
CN108135879A (zh) * | 2015-12-02 | 2018-06-08 | 金印株式会社 | 育发生发促进剂 |
KR20200019097A (ko) * | 2018-08-13 | 2020-02-21 | 토탈바이오 주식회사 | 탈모방지 및 발모제 조성물 |
WO2021235924A1 (en) * | 2020-05-21 | 2021-11-25 | Wipro Manufacturing Services Sdn. Bhd. | Method and compositions for improving scalp health |
-
2022
- 2022-08-03 CN CN202210926224.XA patent/CN115120522A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070036742A1 (en) * | 2005-08-09 | 2007-02-15 | Access Business Group International Llc | Methods and compositions for modulating hair growth or regrowth |
JP2010150177A (ja) * | 2008-12-25 | 2010-07-08 | Maruzen Pharmaceut Co Ltd | Fgf−7産生促進剤、igf−1産生促進剤及びhgf産生促進剤 |
US20140341829A1 (en) * | 2011-12-22 | 2014-11-20 | Akzo Nobel Chemicals International B.V. | Bioactive compositons having hair anti aging activity |
CN108135879A (zh) * | 2015-12-02 | 2018-06-08 | 金印株式会社 | 育发生发促进剂 |
US20180250213A1 (en) * | 2015-12-02 | 2018-09-06 | Kinjirushi Co., Ltd. | Hair restoration/growth stimulating agent |
JP2017066145A (ja) * | 2016-10-07 | 2017-04-06 | 国立大学法人九州大学 | 毛母細胞増殖促進剤、毛乳頭細胞増殖促進剤、脱毛症の外用薬及び脱毛症の外用薬の生産方法 |
KR20200019097A (ko) * | 2018-08-13 | 2020-02-21 | 토탈바이오 주식회사 | 탈모방지 및 발모제 조성물 |
WO2021235924A1 (en) * | 2020-05-21 | 2021-11-25 | Wipro Manufacturing Services Sdn. Bhd. | Method and compositions for improving scalp health |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116999484A (zh) * | 2023-10-07 | 2023-11-07 | 云南英格生物技术有限公司 | 紫苏籽油粕提取物在制备5α-还原酶抑制剂中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120107427A1 (en) | Composition for promoting adipocyte differentiation containing an extract of rehmannia glutinosa, licorice, coicis semen, hordei fructus, chaenomelis fructus, acanthopanacis cortex or puerariae radix | |
CN114404430B (zh) | 一种包含白头翁皂苷b4作为有效成分的促进生发的组合物 | |
CN114288309B (zh) | 一种包含白头翁皂苷b5作为有效成分的促进生发的组合物 | |
KR20150007975A (ko) | 발모 및 육모 촉진용 조성물 | |
JPH04124122A (ja) | 白髪防止黒化剤 | |
JPH10120583A (ja) | 抗アレルギー剤、ケミカルメディエーター遊離抑制剤及びこれを含有する抗アレルギー性化粧料,医薬品並びに食品 | |
CN115120522A (zh) | 木犀草素及衍生物作为有效成分促进生发的组合物及应用 | |
KR20190013575A (ko) | 탈모 방지 또는 발모 촉진용 조성물 | |
CN112220794B (zh) | 柠檬苦素的防脱发和生发用途 | |
KR102179610B1 (ko) | 월견자 및 의이인 정유 혼합물을 함유하는 탈모 예방 또는 발모 촉진용 조성물 | |
BRPI0900583B1 (pt) | Processo cosmético para o tratamento das fibras queratínicas humanas e uso cosmético | |
KR101965594B1 (ko) | 콩 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
HK1254449A1 (zh) | 含有大豆皂苷的生长毛发和/或修复毛发促进用组合物 | |
CN107530253B (zh) | 含有补骨脂定的用于促进生发及/或育发的组合物 | |
BRPI0900541A2 (pt) | composiÇço de cuidado das fibras queratÍnicas humanas, uso cosmÉtico e processo de tratamento cosmÉtico das fibras queratÍnicas humanas e/ou do couro cabeludo | |
CN113058026B (zh) | Kisspeptin-234在促进毛发生长中的应用 | |
WO2023138280A1 (zh) | 促进生发组合物、促进生发药物及应用 | |
JP2546813B2 (ja) | 養毛化粧料 | |
CN112494506A (zh) | 地奥司明的防脱发和生发用途 | |
CN112057463A (zh) | 王不留行黄酮苷的防脱发和生发用途 | |
KR20160026042A (ko) | 락토비온산을 함유하는 항스트레스용 또는 항상성 유지용 조성물 | |
KR102384239B1 (ko) | 오미자, 산수유, 박하 및 월견자 정유 혼합물을 함유하는 탈모 예방 또는 발모 촉진용 조성물 | |
KR102384238B1 (ko) | 오미자, 산수유, 및 익모초 정유 혼합물을 함유하는 탈모 예방 또는 발모 촉진용 조성물 | |
KR101556498B1 (ko) | 아스트라갈로시드 iv를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
CN117838673A (zh) | 瓦伦烯及其衍生物在制备防脱发、生发药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220930 |